Category Archives: Biotechnology

Dublin, March 24, 2020 (GLOBE NEWSWIRE) -- The "Microsphere Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

The global microsphere market is forecast to reach $4.7 billion by 2025 with a CAGR of 7.1% from 2020 to 2025.

According to this market report, the future of the global microsphere market looks promising with opportunities in the composites, medical technology, life science & biotechnology, and painting & coating industries. The major drivers for this market are the growing demand for higher efficiency and lightweight materials and superior structural and enhanced properties of microsphere over conventional fillers.

Emerging trends, which have a direct impact on the dynamics of the industry, include continuous research and development to improve the drug delivery system and the development of biodegradable microspheres.

The study includes trends and forecast for the global microsphere market by product type, end-use industry, material, and the region.

Some of the microsphere companies profiled in this report include 3M, Cospheric, Trelleborg, and AkzoNobel Expancel.

It is forecast that the glass microsphere will remain the largest material segment over the forecast period, as it provides lower viscosity, a high melting point, and higher chemical resistance than other types of microsphere.

Composites is projected to remain the largest end-use industry, and it is also expected to witness the highest growth during the forecast period due to the increasing demand for lightweight materials in various end-use industries.

North America will remain the largest region, and it is also expected to witness the highest growth over the forecast period due to the increasing demand for composites in automobiles and growth in medical technology.

Some of the features of the report include:

This report answers the following 11 key questions:

Q.1 What are some of the most promising potential, high-growth opportunities for the global microsphere market by end-use industry (Composites, Medical Technology, Life Sciences & Biotechnology, Paints & Coatings, Cosmetics & Personal Care, and Others), product type (Hollow Microsphere and Solid Microsphere), material (Glass Microspheres, Polymer Microspheres, Ceramic Microspheres, Fly Ash Microspheres, Metallic Microspheres, and Others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2 Which segments will grow at a faster pace and why?Q.3 Which regions will grow at a faster pace and why?Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the market?Q.5 What are the business risks and threats to the market?Q.6 What are emerging trends in this market and the reasons behind them? Q.7 What are some changing demands of customers in the market?Q.8 What are the new developments in the market? Which companies are leading these developments? Q.9 Who are the major players in this market? What strategic initiatives are being implemented by key players for business growth?

Key Topics Covered

1. Executive Summary

2. Market Background and Classifications2.1: Introduction, Background, and Classification2.2: Supply Chain2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2014 to 20253.1: Macroeconomic Trends (2014-2019) and Forecast (2020-2025)3.2: Global Microsphere Market Trends (2014-2019) and Forecast (2020-2025)3.3: Global Microsphere Market by Product Type3.3.1: Hollow Microspheres3.3.2: Solid Microsphere3.4: Global Microsphere Market by End-use Industry3.4.1: Composites 3.4.2: Medical Technology 3.4.3: Life Sciences and Biotechnology 3.4.4: Cosmetics and Personal Care 3.4.5: Paint and Coatings3.4.6: Others3.5: Global Microsphere Market by Material3.5.1: Glass Microsphere3.5.2: Polymer Microsphere3.5.3: Ceramic Microsphere3.5.4: Fly Ash Microsphere3.5.5: Metallic Microsphere3.5.6: Others

4. Market Trends and Forecast Analysis by Region from 2014 to 20254.1: Global Microsphere Market by Region4.2: North American Microsphere Market4.2.1: Market by End-use Industry4.2.2: Market by Product Type4.2.3: Market by Material4.2.4: The US Microsphere Market4.2.5: Canadian Microsphere Market4.2.6: Mexican Microsphere Market4.3: European Microsphere Market4.4: APAC Microsphere Market4.5: RoW Microsphere Market

5. Competitor Analysis5.1: Product Portfolio Analysis5.2: Market Share Analysis5.3: Geographical Reach5.4: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis6.1: Growth Opportunity Analysis6.1.1: Growth Opportunities for the Global Microsphere Market by End-use Industry6.1.2: Growth Opportunities for the Global Microsphere Market by Product Type6.1.3: Growth Opportunities for the Global Microsphere Market by Material6.1.4: Growth Opportunities for the Global Microsphere Market by Region6.2: Emerging Trends in the Global Microsphere market6.3: Strategic Analysis6.3.1: New Product Development6.3.2: Capacity Expansion in the Global Microsphere market6.3.3: Certification and Licensing6.3.4: Merger and Acquisition

7. Company Profiles of Leading Players7.1: 3M7.2: Potters Industries LLC7.3: AkzoNobel N.V.7.4: Trelleborg AB7.5: Chase Corporation7.6: Matsumoto Yushi-Seiyaku Co. Ltd.7.7: Momentive Performance Materials Inc.7.8: Luminex Corporation7.9: Thermo Fisher Scientific7.10: Sigmund Lindner GmbH

For more information about this report visit https://www.researchandmarkets.com/r/c9ai0o

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View post:
Microsphere Industry Outlook, 2025: Promising Opportunities in the Composites, Medical Technology, Life Science & Biotechnology, and Painting...

The 31 rating InvestorsObserver gives to Vir Biotechnology Inc (VIR) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 12 percent of stocks in the Biotechnology industry, VIRs 31 overall rating means the stock scores better than 31 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 31 means the stock is more attractive than 31 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Vir Biotechnology Inc (VIR) stock is trading at $36.76 as of 12:45 PM on Monday, Mar 23, a drop of -$3.00, or -7.55% from the previous closing price of $39.76. The stock has traded between $36.15 and $39.94 so far today. Volume today is low. So far 218,746 shares have traded compared to average volume of 1,059,947 shares.

To see the top 5 stocks in Biotechnology click here.

Go here to see the original:
Industry Breakdown: Where Does Vir Biotechnology Inc (VIR) Stock Fall in the Biotechnology Field? - InvestorsObserver

Global Animal Health Biotechnology market research report from ResearchMozs perspective

ResearchMoz in its recently published market study offers valuable regional as well as global insights related to the Animal Health Biotechnology market. As per the study, the global Animal Health Biotechnology market is estimated to reach a value of ~US$ XX Mn/Bn in 2019 and projected to grow at a CAGR of XX% over the forecast period, 2019-2029.

The ResearchMoz team consists of highly experienced research analysts who have curated the market by carrying out extensive primary and secondary research. Further, to ensure that the users have a seamless experience while viewing the report, an overview of the Animal Health Biotechnology is provided in the report.

Request Sample Report @https://www.mrrse.com/sample/6077?source=atm

Competitive Analysis

Market segmentation up to the second or third level

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/6077?source=atm

What information does the report on the Animal Health Biotechnology market offer to the readers?

Important queries catered to in the presented market assessment

Buy This Report @ https://www.mrrse.com/checkout/6077?source=atm

Why Choose ResearchMoz?

Excerpt from:
Animal Health Biotechnology Market 2019 by Rising-Trends, Growth Analysis, Industry Share, Product Types, User-Demand, Business Strategy and...

A SpaceX Dragon cargo spacecraft, currently on its way to the International Space Station (ISS) as part of the CRS-20 mission, is carrying a variety of scientific research projects as well as usual food and other supplies for the astronauts. The hardware going to the ISS this weekend includes a number of research projects in biotechnology that could improve the lives of patients here on Earth.

The payloads launching on SpaceX CRS-20 demonstrate that the ISS is not only an amazing multi-purpose, multi-user research facility in low Earth orbit but also a proof-of-concept incubator where industries can advance their applied research and technology development programs, ISS National Lab Chief Operating Officer Ken Shields said in a statement.

Moreover, the diversity of investigations supported by the private sector, government agencies, and academic institutions demonstrates the continued rising demand and interest in utilizing our orbiting laboratory to benefit life on Earth and build a thriving market economy in space.

Expedition 62 Flight Engineer Jessica Meir works with research hardware to support the OsteoOmics-02 bone investigation. NASA

One experiment by the startup Dover Lifesciences is an attempt to develop protein-based drugs to treat metabolic disorders and obesity. Proteins in the human body play a central role in health and disease and they can also be used as biological agents to treat disease, the ISS National Lab explained in a blog post.

By using protein crystallization to understand the structure of proteins alone and in complex with other molecules, scientists can better design therapeutics to prevent and treat disease. In microgravity, protein crystals can grow larger and with fewer imperfections than on Earth, revealing more detailed protein structures.

The research is looking for drugs that could inhibit the conversion of glucose to glycogen in the liver and muscles. If this were possible, it could be used as a treatment for obesity and some rare genetic disorders, and could even have applications in the treatment of cancer.

Other research includes the development of a small drug pump, shaped like a patch, which can deliver medicine in a controlled and continuous way. For people who have conditions that require regular injections, such as diabetes, this patch could offer an easier and safer way to get the medicine they need regularly.

Finally, the company 1Drop Diagnostics is aiming to develop a portable diagnostic device that can make diagnoses based on very small amounts of blood, which would be invaluable to patients and doctors in remote locations who have limited access to lab equipment.

The Dragon cargo spacecraft is set to arrive at the International Space Station at 4 a.m. PT on Monday, March 9.

Follow this link:
The biotechnology experiments that SpaceX is carrying to the ISS this weekend - Yahoo Tech

Yet another biotech has joined the fray against the novel coronavirus: Alnylam Pharmaceuticals (NASDAQ:ALNY) andVir Biotechnology (NASDAQ:VIR) on Wednesday announced they were expanding their ongoing collaboration to include an attempt to develop RNA interference (RNAi) treatments for SARS-CoV-2.

According to the American Society for Microbiology, coronaviruses are everywhere. They are the second-leading cause of the common cold, after rhinoviruses. In an article on the society's website, Dr. Rodney Rhode wrote, "Coronaviruses ... mutate and change at a high rate, which can create havoc for both diagnostic detection as well as therapy (and vaccine) regimens."

Image source: Getty Images

The two companies have been collaborating since the 2017 founding of Vir, which specializes in using immunology to fight and prevent infectious diseases. Vir CEO George Scangos was the CEO ofBiogenbefore he took control of the start-up.

"Given the scope and speed of the COVID-19 outbreak," Scangos said, "Vir is seeking multiple approaches that combine our expertise in infectious disease with that of current and new partners to respond rapidly. Alnylam has been an excellent partner, and our complementary capabilities made this a compelling opportunity..."

As Alnylam CEO John Maraganore said, "We believe RNAi therapeutics represent a promising approach for targeting coronaviruses, like SARS-CoV-2. As the leader in RNAi therapeutics, we at Alnylam are committed to doing our part in joining other biopharmaceutical companies, like Vir, to address this emerging outbreak."

Vir will lead all development and commercialization of any selected drug molecules. Alnylam retains the option to share in the profits and losses associated with the effort. Shares of Vir were up 14% in early trading Wednesday, while Alnylam was up 3%.

{%sfr%)

Read more from the original source:
Vir Biotechnology and Alnylam Join the Fight Against COVID-19 - Motley Fool

The decision to buy or sell a stock is dependent not only on the company fundamentals but also on its trading price. Many strong businesses enter the avoid or sell zone, simply because of exaggerated prices and seemingly little to no upside potential. One such stock that a value investor needs to shy from is Vir Biotechnology (VIR).

Today, we will see why fundamentals fail to justify Vir Biotechnology's valuation levels.

Vir Biotechnology is a clinical-stage immunology company focused on developing novel treatments targeting infectious diseases. The company's four therapeutic platforms, antibody platform, T Cell platform, Innate immunity platform, and siRNA platform, are working on enhancing the immune response to pathogens. The company's lead asset, VIR-2218, is currently being evaluated in Phase 2 in HBV (hepatitis B) indication. Besides, the company also has multiple early-stage investigational drug candidates being evaluated in tuberculosis, influenza, and HIV indications.

Recently, though, the stock has jumped over 100% on news of its involvement in researching antibodies that can work against the novel coronavirus or COVID-19 virus strain.

On February 12, Vir Biotechnology announced that it has identified two monoclonal antibodies that bind to the SARS-CoV-2 virus which causes the COVID-19 disease. These antibodies are targeting the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2. On February 25, the company announced a manufacturing collaboration with WuXi Biologics to advance and produce human monoclonal antibodies for the potential treatment of COVID-19.

Although these are promising developments especially in a world fighting a pandemic, the fact remains that the company is not even close to commencing first-in-human trials for the investigational COVID-19 therapeutic. The company has isolated antibodies from patients who survived SARS and is studying it for COVID-19 in the preclinical stage. The company may require around 10 months, provided everything goes without a glitch, to get the first human dosed with this therapy.

Gilead Sciences (GILD) seems to be much ahead in the quest of COVID-19 therapy. On February 26, the company announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19. In these randomized, open-label, multicenter studies, the company plans to enroll 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March to evaluate two dosing durations of remdesivir, administered intravenously. FDA has already reviewed and accepted the company's IND (investigational new drug) filing for remdesivir for the treatment of COVID-19. This follows the article published in The NEJM (New England Journal of Medicine) which highlighted clinical benefit witnessed by a COVID-19 patient in the U.S. on the administration of remdesivir.

Remdesivir is already being studied in two clinical trials, in China's Hubei province led by the China-Japan Friendship Hospital as well as the recently initiated clinical trial in the United States led by the National Institute of Allergy and Infectious Diseases.

Then, there is Regeneron (REGN), also working on an antibody approach to finding a cure for COVID-19. The company's technology platform demonstrated robust outcomes in the Ebola outbreak of 2015.

There is also much activity in the vaccine space for COVID-19. We also have Moderna Therapeutics (MRNA) working with the NIH (National Institutes of Health) to evaluate mRNA-1273 as a vaccine candidate for COVID-19 in the Phase 1 trial. The company will be studying the vaccine candidate in the healthy-volunteer study expected to begin in April. If proven safe, Moderna and NIH plan to enroll hundreds of more patients to determine whether the vaccine protects against infection. We also see other companies such as Sanofi (SNY), Inovio Pharmaceuticals (INO), CureVac, and GlaxoSmithKline (NYSE:GSK), analyzing various vaccine candidates in the preclinical stage.

Vir Biotechnology is definitely not a forerunner in this race for COVID-19 treatment. Hence, the investor exuberance and the more than 100% jump in share prices since February 24 does not seem justified by company fundamentals.

Vir Biotechnology and Alnylam Pharmaceuticals (ALNY) are working on investigational subcutaneously administered HBV-targeting siRNA (Small interfering RNA), VIR-2218, in Phase 1/2 clinical trial. This drug is designed to inhibit the production of all HBV proteins including HBsAg (HBV surface antigen). HBsAg is developed by the HBV virus to inhibit T-cell activity against the infection.

In January 2020, Vir Biotechnology announced new pipeline data from the ongoing Phase 2 trial of VIR-2218. The data demonstrated substantial reductions in HBsAg and also high tolerability of the therapy. All HBeAg negative and positive patients who received two doses of 200 mg of VIR-2218 reported at least a 1.0 log10 decline in HBsAg as well as a mean decline of 1.5 log10 in HBsAg at day 85.

Further, none of the patients demonstrated ALT (alanine amino transaminase) greater than or equal to three times the upper limit of normal, validating the manageable tolerability profile of the therapy.

Vir Biotechnology expects 16-week data across all cohorts in the first half of 2020. The company also plans to commence two new trials with VIR-2218 by late 2020. These include a Phase 2 trial in China in collaboration with Brii Biosciences, and another Phase 2 combination trial of VIR-2218 and pegylated interferon-alpha (PEG-IFN-). The company is also working on advancing CTA (clinical trial application) for the investigational HBV vaccine, VIR-3434, in the first half of 2020.

Although there are impending milestones and catalysts for Vir Biotechnology in 2020, none of them justify the company's current valuation multiples. Currently, Vir Biotechnology is trading at a price-to-sales multiple of 626.43x and price-to-cash flow multiple of 19.95x.

Other hepatitis B players such as Ionis Pharmaceuticals (IONS), GlaxoSmithKline, Arrowhead Pharmaceuticals (ARWR), and Arbutus Biopharma are trading at much lower price-to-sales multiples of 6.88x, 2.55x, 22.46x, and 30.80x, respectively.

Besides the valuations, there are many other risks associated with this company. Vir Biotechnology is a clinical-stage company and can continue to report losses for many more years. Infectious disease players have historically got the short end of the stick in terms of biopharmaceutical funding. Unlike chronic lifestyle conditions, there may come a stage when a majority of infectious disease patients are cured. We have seen this for the Gilead Sciences Hepatitis C franchise. There remains a high possibility that after the initial bolus of patients, hepatitis B players may also face a rapid decline in the addressable market and extraordinary profits.

The company is also in the early stage of clinical development and faces significant R&D failure risk. It does not have a history of advancing molecules in the late-stage of clinical development or of securing regulatory approvals. The company also does not have experience of successfully commercializing products. This exposes the company to a significant degree of market uncertainty.

One upside for the company, however, is its stable cash balance of around $320 million at the end of September 2019. Assuming that the company's cash burn rate is similar to the cash spent on operational activities of around $120 million in 12 months ending September 2019, the company may not need dilutive financing at least till the end of 2021. However, the company may still choose to go for equity dilution to take advantage of its stratospheric valuations.

According to finviz, the 12-month consensus target price for the stock is $26.33. On February 27, Baird analyst Madhu Kumar downgraded Vir Biotechnology to Underperform from Neutral and reiterated the target price of $17. On February 4, JPMorgan analyst Anupam Rama downgraded Vir Biotechnology to Neutral from Overweight but raised the price target from $25 to $26.

In November 2019, Goldman Sachs analyst Paul Choi initiated coverage with a Buy rating and $37 price target. Barclays analyst Gena Wang initiated coverage with an Overweight rating and $25 price target.

Here again, we see that the modest fiscal 2020 revenue and EPS estimates do not support Vir's high valuations.

In this backdrop, I believe that a target price range of $25 to $28 is a fair estimate of the true growth potential of Vir Biotechnology in 2020. This is definitely a promising biotechnology company, but investors should not pick this company at unsustainable valuations. Instead, it is advisable even for aggressive investors to wait for a better entry point to pick this stock in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

See more here:
Vir Biotechnology: Avoid This Overvalued Stock In March 2020 - Seeking Alpha

New Jersey, United States,-The Nanoparticles in Biotechnology and Pharmaceuticals Market report was created with experience and knowledge by market analysts and researchers. It is a phenomenal compilation of important studies that examine the competitive landscape, segmentation, geographic expansion and sales growth, production and consumption of the Nanoparticles in Biotechnology and Pharmaceuticals market. Players can use the reports accurate market data and numbers, as well as statistical studies, to understand the current and future growth of the Nanoparticles in Biotechnology and Pharmaceuticals market. The report includes CAGR, market share, sales, gross margin, value, volume and other key market numbers that provide a clear picture of the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=3WN&utm_medium=001

Top Key Players of the Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

Our analysts have used advanced primary and secondary research techniques and tools to prepare this report. The sources and research tools we use are extremely reliable. New players can also use this research study to develop business strategies and learn about future market challenges. We offer a complete competitive analysis that includes a detailed company profile of the main players, a study of the nature and characteristics of the supplier landscape and other important studies.

Leading Regions

The research study contains important results and insights from our monitoring and analysis of the market for Nanoparticles in Biotechnology and Pharmaceuticals industry. We have provided key data points, including divestments, launches, enhancements, partnerships, mergers, acquisitions, and other strategic initiatives by players in the Nanoparticles in Biotechnology and Pharmaceuticals market. The report also includes price developments for regional markets and an analysis of important market events at regional and global levels. Our analysis enables you to make informed decisions in the market for Nanoparticles in Biotechnology and Pharmaceuticals in terms of acquisitions, inventory, prices and production. We enable you to offer your opponents tough competition by providing fast, actionable market information in real time.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=3WN&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Customized Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=3WN&utm_medium=001

Highlights of the Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market

Our Trending Reports

IT Training Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more from the original source:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Size, Shares, Key Players, Demand, Supply, Growth and Forecast to 2026 - 3rd Watch News

Dublin, March 05, 2020 (GLOBE NEWSWIRE) -- The "Worldwide Wound Care Market Summary" report has been added to ResearchAndMarkets.com's offering.

Wound care is very much a challenge for both patients and healthcare providers.

Worldwide Wound Care Market Summary identifies a market opportunity for major sectors of this important market. A particular focus is given to biotechnology used in wound care, including advanced biodressings and negative pressure wound systems.

Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth in the market during the report's forecast period. Growth is also being driven by the introduction of portable, single-use products in negative pressure wound therapy.

The report focuses on wound care advancements, providing a table of newly approved wound care products for 2019. The aging of the population and continued advances in biotechnology drive the wound care industry. It is the goal of new and existing product manufacturers to offer products designed to improve healing rates and prevent wound formation.

Market data in the report include:

World Market

Total Market by Segment

Market Segments by Application

Market by Application

The report also contains current market size for the total wound care products market for the following countries and regions:

Worldwide Wound Care Market Summary provides an outline of the competitive market, including the following data points:

Industry participants have attempted to diversify their offerings by acquiring smaller companies with new and innovative technology. This move has created more competition among large wound care companies.

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Total Worldwide Wound Care Market Size, Forecast, and Competitive Analysis

Chapter 3: Wound Care Advancements

Chapter 4: Top Five Company Profiles(Company Overview, Performance Review)

A-Z List of Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/eyoxce

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See more here:
Worldwide Wound Care Market Summary 2017-2024 - Focus on Biotechnology: Advanced Biodressings, Negative Pressure Wound Systems, and More - Yahoo...

PRINCETON, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation(Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that it has been granted U.S. Patent No. 15/702,063 titled Stimulation of an Immune Response by Enantiomers of Cationic Lipids by the United States Patent and Trademark Office (USPTO).

The expansion of our international patent portfolio furthers protects our novel Versamune platform and the development of our robust pipeline, commented Dr. Frank Bedu-Addo, CEO of PDS Biotech. "As we advance our lead program, PDS0101 towards three Phase 2 studies this year with leaders in the field of immuno-oncology, we believe that our Versamune platform holds the potential to significantly improve clinical outcomes for patients.

The U.S. Patent No. 15/702,063 titled Stimulation of an Immune Response by Enantiomers of Cationic Lipids provides protection for compositions of matter for the Versamune platform including its chemical design and methods of delivery including oral, injectable and topical. The patent covers immune activating compositions containing the immunologically active enantiomer of the cationic lipid 1,2-dioleoyl-3-trimethyl-ammonium-propane (R-DOTAP) and a specific antigen. This patent has also been issued in several other countries including the European Union, Japan, Canada and Australia. The PDS Versamune patent portfolio also includes broader cationic lipid compositions that activate the immune system. The combination of Versamune with various antigens forms the basis for PDS Biotechs broad immuno-oncology pipeline, including its lead candidate PDS0101 for the treatment of advanced human papillomavirus (HPV) related cancers.

About PDS Biotechnology

PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotech is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechs pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset, PDS0101; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

Read the original:
PDS Biotechnology Expands Patent Portfolio for its Novel Versamune PlatformGranted Composition of Matter Patent for Versamune Platform by the United...

ANKARA

Turkey's progress in the health sector is strategically critical beyond its economic significance, the Turkish president said on Saturday.

Congratulating the award recipients of the international biotechnology congress BIO Turkey in Istanbul, Recep Tayyip Erdogan in a letter stressed the importance of the pharmaceutical industry for Turkey

Erdogan underlined that the sector was the most important after the defense industry, emphasizing that during difficult times Turkey could only rely on its own production and infrastructure to survive.

"However, we have unfortunately faced veiled resistance in our steps to develop our domestic and national pharmaceutical industry and strengthen our medical device sector, just as we once had in the defense industry," he said.

Attending the ceremony, Vice President Fuat Oktay said that Turkey would act against "approaches" that sought to compel domestic ventures to move abroad even as the government attempted to bring research and development, design and production facilities into the country.

Inviting scientists, non-governmental organizations and universities to support Turkey's biotechnology initiatives, Oktay said investments in the defense, health and food industries would "not only save us from dependency but also turn Turkey into a global exporter."

Health Minister Fahrettin Koca also spoke at the ceremony, underscoring the role of partnerships between academia, industry and individual projects in training a qualified labor force.

After his speech, Koca presented a plaque of appreciation to the representatives of the congress's sponsors.

*Writing by Davut Demircan

View post:
Turkey eager to invest in biotech - Anadolu Agency